Natalia Carballo, MD Sanitas Hospitals/Atrys Health Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of t...
All content for ACE OncoCast is the property of ACE Oncology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Natalia Carballo, MD Sanitas Hospitals/Atrys Health Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of t...
Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 1
ACE OncoCast
26 minutes
1 year ago
Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 1
Episode 1: Opening & Keynote Speech: First-line treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) Enrique Grande, MD, MSc, PhD The therapeutic landscape of unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) has undergone a significant transformation in recent years with the addition of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and novel antibody-drug conjugates (ADCs) to the treatment armamentari...
ACE OncoCast
Natalia Carballo, MD Sanitas Hospitals/Atrys Health Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of t...
